Table 2.
Potential solid tumor targets for CART cell-based therapy.
| Antigen | Cancer |
|---|---|
| CD44v7/8 | Cervical carcinoma |
| DNAM-1 | Prostate carcinoma |
| EGP-40 | Colorectal cancer |
| EpCAM | Prostate cancer |
| FBP | Ovarian cancer |
| FR | Rhabdomyosarcoma |
| GD3 | Melanoma |
| VEGFR2 | Tumor neovasculature |
| LMP-1 | PVR and nectin-2 expressing solid tumors |
| MUC1 | Breast, ovary |
| PSCA | Melanoma, synovial cell sarcoma |
DNAM-1: DNAX accessory molecule-1; EGP-40: epithelial glycoprotein-40; EpCAM: epithelial cell adhesion molecule; FBP: folate-binding protein; LMP-1: latent membrane protein 1; MUC1: mucin 1; PSCA: prostate stem cell antigen.